Omadacycline

證據等級: L5

預測適應症: 10 個

Omadacycline: From Community-Acquired Bacterial Pneumonia to Mycoplasma pneumoniae Pneumonia

One-Sentence Summary

Omadacycline (Nuzyra) is a third-generation tetracycline (aminomethylcycline) originally used to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults. The TxGNN model predicts it may also be effective for Mycoplasma pneumoniae pneumonia — particularly macrolide-resistant cases — with a 99.79% prediction score, currently supported by 0 dedicated clinical trials and 9 relevant publications (mostly case reports and drug-class reviews).

Quick Overview

Item	Content
Original Indication	Community-Acquired Bacterial Pneumonia (CABP), Acute Bacterial Skin and Skin Structure Infections (ABSSSI) — per evidence pack literature/rationale
Predicted New Indication	Mycoplasma pneumoniae pneumonia
TxGNN Prediction Score	99.79%
Evidence Level	L3
Market Status	未上市 (Not Marketed)
Number of Licenses	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data (original_moa) is flagged as a data gap (DG002) and not yet available from DrugBank. However, evidence extracted from the pack’s repurposing rationale indicates that omadacycline, as a third-generation tetracycline, inhibits bacterial 30S ribosomal protein synthesis and has intrinsic in vitro activity against atypical pathogens such as Mycoplasma pneumoniae and Chlamydophila — a well-established class characteristic of tetracyclines, not a novel mechanism.

The original approved indication, CABP, is a broad category that already includes atypical-pathogen pneumonia as part of its causative spectrum. The new predicted indication — M. pneumoniae pneumonia specifically — is therefore mechanistically a subset of the original approved use rather than a distant repurposing target. This is reinforced by rank-6 evidence in the same pack (“post-bacterial disorder”), where the model surfaced omadacycline’s own core registration trials (4 completed Phase 3 RCTs, >2,800 patients across the OASIS program), suggesting the knowledge graph correctly recognizes omadacycline’s established antibacterial efficacy.

The clinical rationale for this specific indication is strongest in the context of macrolide-resistant M. pneumoniae infection, where first-line macrolides fail and tetracyclines serve as an established alternative class. Multiple case reports in the evidence (including pediatric off-label use) describe clinical success with omadacycline in exactly this scenario, which is consistent with — but does not yet constitute controlled-trial proof of — efficacy for this indication.

Clinical Trial Evidence

Currently no related clinical trials registered for Mycoplasma pneumoniae pneumonia specifically.

(Note: 8 clinical trials exist for omadacycline’s core approved indications — CABP and ABSSSI — see rank-6 “post-bacterial disorder” candidate in the source evidence pack; these are not specific to M. pneumoniae pneumonia and are not listed here.)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33512346	2021	Review	The Medical Letter on Drugs and Therapeutics	Overview of antibacterial drug options for community-acquired pneumonia
31169800	2019	Review (Drug Profile)	The Medical Letter on Drugs and Therapeutics	Introductory drug profile of omadacycline (Nuzyra), a new tetracycline antibiotic
37728376	2023	PK Study	Expert Opin Drug Metab Toxicol	Pharmacokinetic evaluation of oral-only omadacycline for CABP; confirms activity against atypical bacteria
37842004	2023	Case Report	Front Cell Infect Microbiol	Adolescent with macrolide-unresponsive M. pneumoniae pneumonia successfully treated with omadacycline
39867285	2025	Case Report (Compassionate Use)	Infect Drug Resist	Down syndrome pre-schooler with critically ill macrolide-resistant M. pneumoniae pneumonia treated via compassionate-use omadacycline
41356655	2025	Case Report	Clin Case Rep	4-year-old with mixed CAP infection and multiple antimicrobial allergies treated with omadacycline
39224609	2024	Case Report	Front Med	Pediatric case of severe M. pneumoniae pneumonia complicated by anti-IgLON5 antibody encephalitis
39789442	2025	Case Report	BMC Infect Dis	Co-infection of Dabie bandavirus and M. pneumoniae, illustrating diagnostic complexity in atypical pneumonia
41710381	2026	Case Report (Adverse Event)	Infect Drug Resist	Anticardiolipin antibody positivity and hypercoagulable state following IV omadacycline for M. pneumoniae pneumonia — safety signal

Safety Considerations

Please refer to the package insert for safety information. Detailed TFDA/regional label warnings, contraindications, and drug-drug interaction data are not yet available (Blocking data gap DG001 — safety review at Stage S1 cannot proceed without this data).

One relevant safety signal was identified in the literature: a case report (PMID 41710381) describes new-onset anticardiolipin antibody positivity and a hypercoagulable state temporally associated with IV omadacycline therapy for M. pneumoniae pneumonia — this warrants monitoring attention but does not yet establish causality.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic basis is sound (tetracyclines have intrinsic activity against M. pneumoniae, and this pathogen falls within omadacycline’s already-approved CABP spectrum), and multiple independent case reports — including compassionate-use in a high-risk pediatric patient — demonstrate real-world clinical success against macrolide-resistant strains. However, no controlled trials exist for this specific indication, use in pediatric patients is currently off-label, and core safety documentation (label warnings, contraindications, DDI) is missing.

To proceed, the following is needed:

TFDA (or applicable local regulator) package insert warnings and contraindications (DG001, blocking)
Confirmed mechanism-of-action documentation from DrugBank (DG002)
A prospective or retrospective controlled study specifically in macrolide-resistant M. pneumoniae pneumonia
Pediatric safety and efficacy data, given the predominance of off-label pediatric case reports in current evidence
Follow-up on the anticardiolipin antibody/hypercoagulability signal (PMID 41710381) before broader use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.